Suppr超能文献

黄连素对新诊断2型糖尿病合并非酒精性脂肪性肝病患者的治疗效果及血液流变学变化的研究

[Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease].

作者信息

Xie Xiaoming, Meng Xiaojun, Zhou Xiaojun, Shu Xiaochun, Kong Hongjuan

机构信息

No. 5 Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2011 Nov;36(21):3032-5.

Abstract

OBJECTIVE

To explore the therapeutic effect and the hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease.

METHOD

Sixty patients, in our department from March 2009 to March 2010, with type 2 diabetes and nonalcoholic fatty liver disease were randomly divided into two groups. One group was given berberine, another group was given Xuezhikang, both for 12 weeks. The indicators, include B-ultrasound of liver, triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspertate aminotransferase (AST), hemorrheology, were detected before and after treatment.

RESULT

After treatment by berberine, B-ultrasound of liver were better than before, the effective rate was 70%, vs 73.3% after treatment by Xuezhikang. ALT, AST, TC, TG, LDL-L, hemorrheology (including the whole blood viscosity, whole blood viscosity, high cutting reduction of whole blood viscosity, plasma cutting reductive low viscosity, blood sedimentation, RBC deposited, fibrinogen) were significantly lower than before, however, HDL-L significantly increased (P<0.05). The therapeutic effect of xuezhikang was the same as berberine. The distance between the indicators of the two groups was no different.

CONCLUSION

Berberine can obviously improve the conditions of new diagnostic T2DM patients with nonalcoholic liver lesions, effectively reduce hemorrheology indicators, and has good application prospect.

摘要

目的

探讨黄连素对新诊断的2型糖尿病合并非酒精性脂肪性肝病患者的治疗效果及血液流变学变化。

方法

选取2009年3月至2010年3月在我科就诊的60例2型糖尿病合并非酒精性脂肪性肝病患者,随机分为两组。一组给予黄连素,另一组给予血脂康,均治疗12周。检测治疗前后肝脏B超、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、血液流变学等指标。

结果

黄连素治疗后肝脏B超较治疗前好转,有效率为70%,血脂康治疗后有效率为73.3%。ALT、AST、TC、TG、LDL-L、血液流变学(包括全血黏度、全血黏度、全血高切还原黏度、血浆切变率低黏度、血沉、红细胞沉降、纤维蛋白原)较治疗前明显降低,HDL-L明显升高(P<0.05)。血脂康的治疗效果与黄连素相同。两组指标之间的差异无统计学意义。

结论

黄连素可明显改善新诊断的2型糖尿病合并非酒精性肝损伤患者的病情,有效降低血液流变学指标,具有良好的应用前景。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验